References
  1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000; L018(43):1–6.
  2. Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Official J Eur Union. 2009 Jul 3;52:7–10. Availablefrom: http://eurlex.europa.eu/legalcontent/EN/TXT/?uri=OJ:C:2009:151:TOC , accessed 30 April 2021.
  3. https://rarediseases.info.nih.gov/diseases.
  4. Orphan Drug Act of 1983. US Food and Drug Administration. 4 January 1983.
  5. Richter T, Nestler-Parr S, Babela R; International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Health 2015; 18:906-14. doi: 10.1016/j.jval.2015.05.008.
  6. https://rarediseases.org.
  7. Crea F. Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue. Eur Heart J. 2021; 42:1533-1537. doi: 10.1093/eurheartj/ehab214.
  8. Garcia-Pavia P, Rapezzi C, Adler et al Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2140.
  9. van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, van Veldhuisen DJ, van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M. Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. Eur Heart J 2019;40:1287–1293.
  10. Emdin M, Aimo A, Rapezzi C et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 2019;40:3699–3706.
  11. Smith A, Balmforth D, Treibel T, Lall K, Oo A, Ambekar S. Cardiac amyloidosis in non-transplant cardiac surgery. J Card Surg 2021 (In press).
  12. Vaidya GN, Patel JK, Kittleson M et al. Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clin Transplant. 2021 Apr 7:e14308. doi: 10.1111/ctr.14308.
  13. Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020; 10(11):118. doi: 10.1038/s41408-020-00385-0.
  14. Cheung RY, Cohen J, Illingworth P. Orphan Drug Plicies: Implications fort he United States, Canada and developing countries. Health Law J 2004;12:183-200.